Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 23;138(6):885–900. doi: 10.1007/s00401-019-02061-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 5 — Activation of the mTOR pathway in FCD2/HME cases. pS6 (pS6 ^Ser240/244) immunostaining on 4 μm-FFPE brain sections in panel-negative (a–c) and panel-positive FCD2/HME cases (d–i). Strong pS6 immunoreactivity in DNs and BCs was detected in all cases, though signals appeared less intense in BCs. Panel-negative representative cases are shown to illustrate: FCD2a in a (FCD-40), FCD2b in b (FCD-68) and HME in c (HME-80). Panel-positive representative cases: FCD2a MTOR:p.Ser2215Phe in d (FCD-24), FCD2b MTOR:p.Thr1977Lys in e (FCD-56), FCD2a DEPDC5:p.Arg239* in f (FCD-35). HME cases with variants in different genes are reported in panels g–i: PIK3CA:p.Glu542Lys in g (HME-75), AKT3:p.Glu17Lys in h (HME-74); RHEB:Tyr35Leu in i (HME-79). Scale bar: 50 µm